Dual-energy X-ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma

European Journal of Haematology

Volumn 88, Issue 5, 2012, Pages 388-395

  Laroche, Michel ^a   Lemaire, Olivia ^a   Bourin, Philippe ^b   Corre, Jill ^a   Gadelorge, Mélanie ^b   Roussel, Muriel ^a   Attal, Michel ^a  

^a CHU PURPAN   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Autologous stem cell transplantation; Bone markers; Dual energy X ray absorptiometry; Multiple myeloma; Phosphorus and calcium status

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; BORTEZOMIB; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DEXAMETHASONE; DICKKOPF 1 PROTEIN; MELPHALAN; PHOSPHORUS;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DENSITY; BONE TURNOVER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; HYPERPARATHYROIDISM; LUMBAR SPINE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT DURATION; VITAMIN D DEFICIENCY;

ABSORPTIOMETRY, PHOTON; BONE REMODELING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; TRANSPLANTATION, AUTOLOGOUS;

EID: 84859625277     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01751.x     Document Type: Article

References (31)

1. Laroche M, Pouillès JM, Dromer C, Attal M, Ribot C. Dual-energy X-ray absorptiometry in patients with multiple myeloma and benign gammopathies. Clin Exp Rheumatol 1996;14:108.
2. Bagni B, Scutellari PN, Orzincolo C, et al. [Quantitative analysis of bone density in multiple myeloma]. Radiol Med 1990;80:432-40.
3. Scutellari PN, Orzincolo C, Bagni B, et al. [Bone disease in multiple myeloma. A study of 237 cases]. Radiol Med 1992;83:542-60.
4. Abildgaard N, Brixen K, Kristensen JE, Vejlgaard T, Charles P, Nielsen JL. Assessment of bone involvement in patients with multiple myeloma using bone densitometry. Eur J Haematol 1996;57:370-6.
5. Holmes JA, Evans WD, Coles RJ, Ramsahoye B, Whittaker JA. Dual energy X-ray absorptiometry measurements of bone mineral density in myeloma. Eur J Haematol 1994;53:309-11.
6. Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK. Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity. Br J Haematol 1997;97:641-8.
7. Dhodapkar MV, Weinstein R, Tricot G, et al. Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 1998;32:121-7.
8. Roux S, Bergot C, Fermand JP, Frija J, Brouet JC, Mariette X. Evaluation of bone mineral density and fat-lean distribution in patients with multiple myeloma in sustained remission. J Bone Miner Res 2003;18:231-6.
9. Mariette X, Khalifa P, Ravaud P, et al. Bone densitometry in patients with multiple myeloma. Am J Med 1992;93:595-8.
10. Mariette X, Bergot C, Ravaud P, et al. Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 1995;76:1559-63.
11. Terpos E, Politou M, Szydlo R, et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004;18:1420-6.
12. Abildgaard N, Glerup H, Rungby J, et al. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma. Eur J Haematol 2000;64:121-9.
13. Abildgaard N, Brixen K, Eriksen EF, Kristensen JE, Nielsen JL, Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004;89:567-77.
14. Abildgaard N, Brixen K, Kristensen JE, Eriksen EF, Nielsen JL, Heickendorff L. Comparison of five biochemical markers of bone resorption in multiple myeloma: elevated pre-treatment levels of S-ICTP and U-Ntx are predictive for early progression of the bone disease during standard chemotherapy. Br J Haematol 2003;120:235-42.
15. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66:337-41.
16. Jakob C, Zavrski I, Heider U, et al. Bone resorption parameters [carboxy-terminal telopeptide of type-I collagen (ICTP), amino-terminal collagen type-I telopeptide (NTx), and deoxypyridinoline (Dpd)] in MGUS and multiple myeloma. Eur J Haematol 2002;69:37-42.
17. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909-14.
18. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 2000;96:2697-702.
19. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-64.
20. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
21. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
22. Badros A, Goloubeva O, Terpos E, Milliron T, Baer MR, Streeten E. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br J Haematol 2008;142:492-4.
23. Abe Y, Ejima E, Fujiyama K, et al. Parathyroidectomy for primary hyperparathyroidism induces positive uncoupling and increases bone mineral density in cancellous bones. Clin Endocrinol (Oxf) 2000;52:203-9.
24. Minisola S, Dionisi S, Pacitti MT, et al. Gender differences in serum markers of bone resorption in healthy subjects and patients with disorders affecting bone. Osteoporos Int 2002;13:171-5.
25. Adami S, Bianchi G, Brandi ML, et al. Determinants of bone turnover markers in healthy premenopausal women. Calcif Tissue Int 2008;82:341-7.
26. Laroche M. [Hétérogénéité du remodelage osseux dans l'ostéoporose masculine idiopathique]. Rev Rhum 2008;75:1035.
27. Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodelling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;10:1700-12.
28. Lundt T, Soe K, Abildgaard N, Garnero P, Pedersen PT, Ormstrup T, Delaissé JM, Plesner T. First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol 2010;85:68-75.
29. Roodman GD. Osteoblast function in myeloma. Bone 2011;48:135-40.
30. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006;108:3992-6.
31. Lemaire O, Laroche M. DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma. Eur J Haematol 2009;84:276-7.